March 03, 2017
A proposed class of Geron Corp. investors have sought approval in California federal court for a $6.25 million settlement regarding claims that the company improperly touted a cancer drug before the U.S. Food and Drug Administration halted a clinical trial over liver toxicity concerns.
April 10, 2015
A California federal judge on Friday trimmed a consolidated proposed shareholder class action accusing Geron Corp. of improperly touting the prospects of its cancer drug imetelstat before the U.S. Food and Drug Administration put a hold on the drug's clinical trial over concerns of liver toxicity.
March 19, 2014
Geron Corp. was hit with a shareholder class action Friday in California federal court accusing the drugmaker of improperly touting the prospects of its sole drug candidate before the U.S. Food and Drug Administration put a hold on the drug's clinical trial over concerns of liver toxicity.